广济药业主营维生素B2、B6及医药制剂产品，广泛应用于医药原料药、饲料添加剂和食品添加剂等领 域。公司旗下拥有武穴、孟州等四个生产基地，主导产品包括不同等级的核黄素及其衍生物，以及口服 固体制剂和大输液类产品。 经观健康 广济药业（000952）(000952.SZ)近期公布了一项总额不超过6亿元的定向增发方案，旨在从其控股股东 长江产业投资集团获取资金支持。作为全球维生素B2的主要供应商之一，广济药业近期发布2025年业 绩预告，预计全年将出现3.99亿元至5.18亿元的亏损。 根据广济药业发布的《2026年向特定对象发行A股股票预案》，此次定增的发行对象为湖北省国资旗下 的长江产业集团，该集团目前持有公司25.26%的股份，是其主要股东。本次定增定价基准日为第十一 届董事会第十五次(临时)会议决议公告日，发行价格为6.32元/股，不低于前20个交易日股票均价的 80%。拟发行股份数量上限为94,936,708股，不超过公司总股本的30%，最终数量将在通过深交所审核 并获得证监会注册后由公司董事会与保荐机构协商确定。 自2023年以来，由于维生素B2市场价格持续低迷，广济药业已连续三年出现净利润亏损，且亏损 ...

广济药业（000952）(000952.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的甲钴胺片 的《药品注册证书》。本次甲钴胺片《药品注册证书》的获批，标志着公司在周围神经疾病治疗领域的 产品布局取得重要进展，为国内患者提供高质量的国产药物选择。 ...

格隆汇2月12日丨福安药业(300194.SZ)公布，全资子公司福安药业集团庆余堂制药有限公司、福安药业 集团宁波天衡制药有限公司、福安药业集团烟台只楚药业有限公司、福安药业集团湖北人民制药有限公 司于近日参与了国家组织集采药品1-8批协议期满品种接续采购的投标工作，根据国家组织集采药品协 议期满品种接续采购办公室（简称"接续采购办公室"）于2026年2月10日发布的《国家组织集采药品协 议期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》显示，公司子公司共计28个药品品种拟中选 本次接续采购。 ...

智通财经APP讯，广济药业(000952.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的甲钴 胺片的《药品注册证书》。本次甲钴胺片《药品注册证书》的获批，标志着公司在周围神经疾病治疗领 域的产品布局取得重要进展，为国内患者提供高质量的国产药物选择。 ...

Core Viewpoint - The news highlights the submission of SHR-1918, a new lipid-lowering drug developed by Shengdi Pharmaceutical, a subsidiary of Heng Rui Medicine, for the treatment of homozygous familial hypercholesterolemia (HoFH) in adults and adolescents aged 12 and above [1][2]. Group 1: Drug Development and Approval - SHR-1918 is an ANGPTL3 monoclonal antibody that lowers triglyceride (TG) levels and low-density lipoprotein cholesterol (LDL-C) levels by inhibiting the activity of ANGPTL3, which plays a crucial role in lipid metabolism [2][7]. - The drug received breakthrough therapy designation for HoFH from the CDE in September 2024 and was included in priority review last month [2][7]. - A Phase III registration study for SHR-1918 began in December 2024 and was marked as "completed" in November 2025, with results yet to be disclosed [5][10]. Group 2: Clinical Trial Results - A single-arm, non-randomized Phase II clinical study showed that after 12 weeks of treatment with SHR-1918 (600mg, subcutaneously every 4 weeks), LDL-C levels decreased by 59.09% [3][8]. - In a randomized controlled Phase II clinical study, after 16 weeks of treatment, LDL-C levels were reduced by 21.7%, 27.3%, 29.9%, and 22.5% for the 150mg, 300mg, 600mg (every 4 weeks), and 600mg (every 8 weeks) dosage groups, respectively [3][8]. Group 3: Market Context and Competition - HoFH is a rare and severe genetic disorder characterized by a defect or absence of low-density lipoprotein cholesterol receptors (LDLR), leading to increased LDL-C levels in the blood and heightened risk of heart disease and stroke [6][12]. - Current treatment options for HoFH include statins, ezetimibe, lomitapide, mipomersen, PCSK9 monoclonal antibodies, and evinacumab, with evinacumab being the only marketed ANGPTL3 monoclonal antibody, projected to generate $162 million in U.S. sales by 2025 [6][12].

本报讯 （记者梁傲男）在当前临床实践中，2型糖尿病的治疗往往高度依赖"逐步加药"的传统路径，许 多患者往往在血糖长期控制不理想、并发症风险逐步累积后，才进入更强效的治疗阶段。 但近年来，围绕糖尿病早期管理的讨论正在发生重要转变，越来越多研究提示，治疗起点的选择不仅影 响短期血糖控制，更深刻关联患者远期并发症风险与整体预后。2型糖尿病临床管理策略正从"后期补 强"的路径，转向"起点即干预"的新范式。 2月11日，礼来创新双靶点药物穆峰达 （替尔泊肽注射液）获得中国国家药品监督管理局批准，新增用 于成人2型糖尿病（T2DM）单药治疗。这一适应症的获批，标志着该药物完成了从联合治疗到单药起 始的完整循证布局，为中国早期糖尿病患者提供了"起点即优效"的全新治疗选择。 该批准基于专门面向中国早期T2DM患者开展的SURPASS-CN-MONO研究，该研究由中国人民解放军 总医院内分泌科主任母义明教授牵头展开，覆盖全国28家研究中心，纳入200余例中国成人T2DM患 者。 研究结果显示，经过40周治疗，患者在血糖水平和体重方面均取得具有临床意义的改善，同时未观察到 低血糖风险增加。 母义明指出，早期血糖控制对于糖尿病患者 ...

Core Viewpoint - Yiling Pharmaceutical officially launched the "Lianhua Qingxie, Healthy China Year" brand communication plan during the 2026 Spring Festival, promoting its core products Lianhua Qingwen and Lianhua Qingke across various media platforms to enhance public awareness of respiratory health [1][4]. Group 1: Company Overview - Yiling Pharmaceutical has adhered to the corporate mission of "inheritance and innovation for the benefit of humanity" for over 30 years, focusing on a market-leading and technology-driven innovation development strategy [4]. - The company has established a comprehensive operational model integrating theory, clinical practice, new drug development, industry, and education, forming a development cluster from medicine to pharmaceuticals to health [4]. Group 2: Product Highlights - Lianhua Qingwen, developed under the guidance of traditional Chinese medicine's network disease theory, is recognized for its broad-spectrum antiviral properties, effectively alleviating symptoms of colds and flu [4]. - The product has been included in national treatment guidelines for infectious public health events 36 times, gaining widespread recognition for its efficacy and safety [4]. - Lianhua Qingke is another innovative traditional Chinese medicine that alleviates cough and phlegm symptoms associated with respiratory diseases, demonstrating triple efficacy in clearing the lungs, phlegm, and cough [6]. Group 3: Market Recognition - The Lianhua brand has received multiple industry awards and is recognized by both medical professionals and consumers, being named a preferred cold medicine in various rankings [8]. - The brand's strong presence in the Spring Festival communication matrix signifies an elevation in its influence and credibility, reflecting the company's commitment to upgrading respiratory health services and contributing to the construction of a healthy China [8].

Core Insights - Korean investors have shown significant interest in various stocks and ETFs listed on the Hong Kong Stock Exchange, with the top ten purchases reflecting a diverse range of sectors and companies [1] Group 1: Top Purchases by Korean Investors - The top purchase by Korean investors is MiniMax-WP, with an investment amount of 2,067.12 million USD [1] - The second highest investment is in 华夏沪深300ETF, totaling 1,918.22 million USD [1] - 澜起科技 ranks third with an investment of 1,864.71 million USD [1] - 安硕恒生科技ETF is the fourth most purchased, with an investment of 736.47 million USD [1] - The fifth position is held by 南方东英每日杠杆三星电子, with an investment of 732.50 million USD [1] - 英诺赛科 received 416.63 million USD in investments, placing it sixth [1] - The seventh position is Premia中国科创50ETF, with an investment of 337.95 million USD [1] - 药明合联 follows in eighth place with 312.55 million USD [1] - 歌礼制药 is ninth, attracting 244.78 million USD [1] - Finally, Global X中国半导体ETF rounds out the top ten with an investment of 207.11 million USD [1]

Core Viewpoint - The article highlights the launch of a public welfare initiative by Yangtze River Pharmaceutical Group in collaboration with Gansu Provincial Radio and Television Station, aimed at ensuring a safe and warm return home for travelers during the Spring Festival travel rush [1][3]. Group 1: Public Welfare Initiative - Yangtze River Pharmaceutical Group focuses on the travel needs of returning home passengers by providing health products such as Huangqi essence and Lanfeng throat lozenges as health gift packages at major transportation hubs [3][5]. - The initiative includes online real-time connections with frontline workers in transportation sectors to promote safety and travel tips, ensuring a smooth and orderly Spring Festival travel [3][5]. Group 2: Community Engagement - The event features a "wish card area" where returning travelers can express their hopes for the new year, fostering a sense of community and warmth [5]. - Yangtze River Pharmaceutical has been providing "Love Bus" services for employees returning home during the Spring Festival for over ten years, extending this warmth to the broader public [5]. Group 3: Corporate Social Responsibility - The company adheres to its mission of "seeking progress and protecting lives" by actively engaging in various public welfare activities, including disaster relief and educational support [7]. - Through foundations like the Longfeng Happiness Children's Fund and the "Mirror People Encouragement" Education Fund, the company aims to assist vulnerable groups and spread warmth and hope [7].

硫酸阿米卡星注射液对多数氨基糖苷类钝化酶稳定，是临床治疗对多种氨基糖苷类抗生素耐药的革兰阴 性杆菌所致严重感染的重要用药，目前在我国基层医疗单位中应用广泛。此次硫酸阿米卡星注射液顺利 过评，标志着华中药业在抗感染类药物研发领域取得又一重要进展。 近日，中国兵器华中药业收到国家药品监督管理局核准签发的通知书，硫酸阿米卡星注射液成功通过仿 制药质量和疗效一致性评价。 下一步，华中药业将继续坚持创新驱动，加快推进各类在研药品的审评进程，持续丰富优质药品供给， 为保障公众健康、推进健康中国建设贡献力量。(华中药业) ...